Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $44
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and lowers the price target from $47 to $44.
Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and lowers the price target from $47 to $44.